ResMed
657 hedge funds and large institutions have $13B invested in ResMed in 2023 Q3 according to their latest regulatory filings, with 60 funds opening new positions, 248 increasing their positions, 253 reducing their positions, and 123 closing their positions.
23% more call options, than puts
Call options by funds: $115M | Put options by funds: $93.7M
2% less repeat investments, than reductions
Existing positions increased: 248 | Existing positions reduced: 253
5.23% less ownership
Funds ownership: 64.9% → 59.67% (-5.2%)
10% less funds holding
Funds holding: 731 → 657 (-74)
11% less funds holding in top 10
Funds holding in top 10: 9 → 8 (-1)
37% less capital invested
Capital invested by funds: $20.8B → $13B (-$7.81B)
51% less first-time investments, than exits
New positions opened: 60 | Existing positions closed: 123
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$213M |
| 2 |
Two Sigma Investments
New York
|
+$129M |
| 3 |
Two Sigma Advisers
New York
|
+$110M |
| 4 |
Voloridge Investment Management
Jupiter,
Florida
|
+$86.5M |
| 5 |
D.E. Shaw & Co
New York
|
+$84.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WCM Investment Management
Laguna Beach,
California
|
-$769M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$413M |
| 3 |
Capital World Investors
Los Angeles,
California
|
-$379M |
| 4 |
OCBV
Ownership Capital B.V.
Amsterdam,
Netherlands
|
-$330M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$132M |
RMD Hedge Fund Activity: Q3 2023 in Review
657 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in ResMed (RMD) for Q3 2023, worth a combined $13B — down 37% from $20.8B a quarter earlier.
Sellers outnumbered buyers: 123 funds closed out of RMD and 60 opened new positions — a net loss of 63 holders — while 253 trimmed existing stakes and 248 added.
The largest buyer was Morgan Stanley, adding an estimated $213M. The largest seller was WCM Investment Management, exiting entirely with an estimated $769M sold.
- 657 institutional investors held ResMed (RMD) as of Q3 2023, down from 731 in Q2 2023.
- Funds reported $13B of ResMed stock for Q3 2023, down 37% quarter-over-quarter.
- 60 funds opened new ResMed positions in Q3 2023 and 123 closed out, a net change of -63 holders.
- The largest ResMed buyer in Q3 2023 was Morgan Stanley, an estimated $213M added.
- The largest ResMed seller in Q3 2023 was WCM Investment Management, an estimated $769M sold.
Based on aggregated 13F filings for Q3 2023.